Dr. Carlos Ramos | EBMT 2018 | CD30-specific CAR redirected lymphocytes
Mar 26, 2018
- Dr Ramos talks about recent work on CD30-specific CARs that is being developed in the treatment of lymphoma and other cancers.
- He noted that there is a lot of data on CD19 however, other proteins have been more difficult to target.
- From the study results, he found that chemotherapy given to patients before infusion showed improved activity and expansion and that lead to better results.
44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, PT
Doctor Carlos Ramos, Baylor College of Medicine, Houston, TX, USA
Download this article:
You can now download this article in Adobe PDF® format.
Download as PDF